rs72553883 — TNFRSF13B A181E
Transmembrane domain missense variant in TACI that abolishes NF-κB signaling, impairing B-cell class switching and antibody production; associated with common variable immunodeficiency and selective IgA deficiency
See your personal result for TNFRSF13B
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
TACI A181E — Disrupted B-Cell Signaling and Antibody Deficiency Risk
TACI (Transmembrane Activator and CAML Interactor) is a receptor on B cells that functions as a critical switch for antibody class switching and the production of T-independent antibody responses. When TACI binds its natural ligands — BAFF and APRIL11 BAFF and APRIL
B-cell Activating Factor and A Proliferation-Inducing Ligand, both members of the TNF superfamily expressed by innate immune cells; BAFF is also called BLyS (B Lymphocyte Stimulator) — it activates NF-κB signaling inside B cells, driving them to switch from producing IgM to producing IgG and IgA. The A181E variant (rs72553883) introduces a glutamic acid in place of alanine at position 181, disrupting the transmembrane domain of the protein where this intracellular signaling is coordinated. The result is a TACI receptor that can bind its ligands but cannot relay the activation signal — leaving B cells unable to mount normal class-switching responses.
The Mechanism
Unlike the related C104R variant22 C104R variant
rs34557412 (p.Cys104Arg) — a different TNFRSF13B mutation that disrupts ligand binding itself, found in 4–5% of CVID patients; A181E and C104R together account for over 90% of CVID-associated TNFRSF13B variants, the A181E protein reaches the B-cell surface and binds BAFF and APRIL normally. The problem lies downstream: the mutation introduces a negative glutamic acid residue into the transmembrane domain, disrupting constitutive and ligand-induced NF-κB activation33 the mutation introduces a negative glutamic acid residue into the transmembrane domain, disrupting constitutive and ligand-induced NF-κB activation
Fluorescence resonance energy transfer studies show impaired intracellular domain clustering; NF-κB response to APRIL stimulation is undetectable in cells expressing A181E vs. dose-dependent response in wildtype. This impairs the intracellular clustering of TACI's cytoplasmic domain that normally assembles signaling complexes with CAML and TRAF6.
Heterozygous carriers of A181E show elevated frequencies of polyreactive and anti-nuclear antibodies in new emigrant and transitional B cells44 elevated frequencies of polyreactive and anti-nuclear antibodies in new emigrant and transitional B cells
These autoreactive B cells are normally culled in the bone marrow through central tolerance; A181E heterozygotes show elevated polyreactive and ANA-positive B cells at a stage where wildtype TACI hemizygotes do not — suggesting A181E protein exerts dominant-negative effects on wildtype TACI, which is not seen in individuals who simply lack one functional TACI copy (hemizygotes). This distinction suggests that the A181E protein actively interferes with normal TACI function rather than merely reducing its quantity — making the mechanism closer to dominant-negative than to simple haploinsufficiency.
The Evidence
The founding study by Castigli et al. (2005)55 Castigli et al. (2005)
First demonstration of TNFRSF13B mutations in CVID; B cells from carriers failed to produce IgG or IgA after APRIL stimulation despite normal surface TACI expression established that TACI mutations prevent B cells from producing IgG and IgA in response to APRIL, even when surface receptor expression and ligand binding appear intact. Among 564 patients with antibody deficiency, A181E was found in 13 patients (2.3%) versus 7 of 675 controls (1.0%)66 A181E was found in 13 patients (2.3%) versus 7 of 675 controls (1.0%)
C104R showed stronger enrichment: 26 patients (4.6%) vs 6 controls (0.9%), P<0.001; A181E enrichment was not statistically significant in this specific cohort. A larger meta-analysis of 1,439 CVID patients and 3,558 controls found A181E significantly enriched in patients (OR 5.60, 95% CI 2.99–10.51) when examining well-characterized cohorts.
Murine studies with the A181E equivalent mutation A144E77 A181E equivalent mutation A144E
Human position 181 = murine position 144; the transmembrane domain is structurally conserved; the A144E mutation in mice reproduces the human A181E biochemical phenotype including impaired NF-κB activation confirmed that transgenic mice carrying this mutation had significantly reduced serum IgA levels, impaired IgG1 responses to polysaccharide antigens, and reduced B-cell proliferation in response to APRIL — closely mirroring what is observed in human A181E carriers.
Clinical data show that heterozygous carriers present across a spectrum: from fully healthy individuals to those with selective IgA deficiency, to overt CVID with recurrent sinopulmonary infections. The index case in the original TACI/A181E literature presented with recurrent pneumonia, otitis media, and chronic Haemophilus influenzae sinusitis88 recurrent pneumonia, otitis media, and chronic Haemophilus influenzae sinusitis
Classic pattern of T-independent antibody deficiency: encapsulated bacteria (H. influenzae, Streptococcus pneumoniae) that normally require polysaccharide-specific IgA and IgG2 for mucosal clearance. A key clinical nuance: monoallelic (heterozygous) A181E carriers show higher rates of autoimmune manifestations — particularly thrombocytopenia and lymphoproliferation — compared to biallelic carriers, who tend toward pure antibody deficiency with paradoxically lower autoimmunity rates.
Practical Implications
The A181E variant is rare globally (approximately 0.5% allele frequency) but clinically significant when present. Most heterozygous carriers have near-normal immunoglobulin levels and no obvious immunodeficiency. The variant functions as a susceptibility allele that requires additional genetic or environmental cofactors to manifest as overt disease. However, a subset of carriers — particularly those with concurrent infections, autoimmune triggers, or additional immune-related variants — may develop measurable immune dysfunction.
Monitoring serum IgG, IgA, and IgM levels provides the most direct readout of TACI function. IgA is particularly sensitive, since TACI-dependent class switching to IgA at mucosal surfaces is a key APRIL-driven function. Vaccination response testing with unconjugated pneumococcal polysaccharide (PPV23) — which activates T-independent IgG2/IgA responses through the same pathway TACI controls — provides a functional measure of whether the variant is causing clinically meaningful B-cell impairment.
Interactions
A181E interacts with the related C104R variant (rs34557412) in compound heterozygosity. Compound A181E/C104R heterozygotes show a more penetrant antibody deficiency phenotype than simple monoallelic carriers. Among patients with biallelic mutations (including compound heterozygotes), the clinical picture typically consists of pure hypogammaglobulinemia with relatively lower autoimmunity burden, while monoallelic A181E carriers show paradoxically higher rates of autoimmune manifestations including thrombocytopenia and lymphoproliferation. This distinction has been attributed to the dominant-negative mechanism of A181E, which — even in the heterozygous state — disrupts wildtype TACI's role in central B-cell tolerance.
Genotype Interpretations
What each possible genotype means for this variant:
Standard TACI signaling; no increased risk for TACI-associated antibody deficiency
You carry two copies of the reference G allele at rs72553883, meaning your TACI transmembrane domain is intact and your B cells respond normally to BAFF and APRIL stimulation. Your immunoglobulin class-switching capacity and T-independent antibody responses are unaffected by this variant. This is the most common genotype globally, carried by approximately 99% of people.
Two copies of the TACI A181E variant; significantly impaired B-cell signaling with high penetrance for antibody deficiency
With both TACI alleles bearing the A181E mutation, the signaling defect is complete for the APRIL-TACI-NF-κB axis. Animal models of the equivalent biallelic mutation (A144E/A144E in mice) demonstrate severely reduced serum IgA, profoundly impaired IgG1 antibody responses to T-independent polysaccharide antigens, and negligible B-cell proliferation following TACI ligation. This translates clinically to the full CVID picture: hypogammaglobulinemia, absent vaccine responses to polysaccharide antigens, and recurrent sinopulmonary infections.
Paradoxically, biallelic TACI mutation carriers show lower rates of autoimmune complications compared to monoallelic (heterozygous) carriers — likely because the dominant-negative effect responsible for central tolerance disruption requires the presence of one wildtype TACI allele to disrupt. In biallelic carriers, the phenotype is more purely one of antibody deficiency. Immunoglobulin replacement therapy (IgRT) is the established treatment for symptomatic hypogammaglobulinemia, reducing recurrent infection rate and preventing progressive lung damage.
One copy of the TACI A181E variant; mildly impaired B-cell signaling with increased risk for antibody deficiency
The A181E mutation introduces a charged glutamic acid residue into the hydrophobic transmembrane domain of TACI at position 181. Functional studies show the mutant protein cannot activate NF-κB in response to APRIL stimulation, even though it is expressed on the cell surface and binds ligand normally. In heterozygous individuals, this dominant-negative disruption of wildtype TACI signaling leads to elevated frequencies of polyreactive and antinuclear B cells in the transitional compartment — a central tolerance defect explaining why heterozygous A181E carriers have higher rates of autoimmune manifestations (thrombocytopenia, lymphoproliferation) than individuals who simply lack one TACI allele.
Serum IgA is the most sensitive early indicator of TACI dysfunction, as mucosal IgA class switching is strongly APRIL/TACI-dependent. A subset of heterozygous A181E carriers present with selective IgA deficiency before developing broader antibody deficiency. Annual serum immunoglobulin measurement (IgG, IgA, IgM) provides a practical surveillance approach. Pneumococcal polysaccharide (PPV23) vaccine response testing — checking pre- and 4-week post-vaccination IgG titers to at least 12 serotypes — gives a direct functional read of T-independent antibody capacity.